Ju Long, Suo Zhimin, Lin Jian, Liu Zhanju
Center for Inflammatory Bowel Disease Research and Department of Gastroenterology, Shanghai Tenth People's Hospital of Tongji University, Shanghai 200072, China.
Department of Gastroenterology, Huaihe Hospital of Henan University, Kaifeng 475000, China.
Precis Clin Med. 2024 Sep 23;7(3):pbae023. doi: 10.1093/pcmedi/pbae023. eCollection 2024 Sep.
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract, and its pathogenesis is believed to be associated with an imbalance between commensal organisms and the intestinal immune system. This imbalance is significantly influenced by the intestinal microbiota and metabolites and plays a critical role in maintaining intestinal mucosal homeostasis. However, disturbances in the intestinal microbiota cause dysregulated immune responses and consequently induce intestinal inflammation. Recent studies have illustrated the roles of the intestinal microbiota in the pathogenesis of IBD and underscored the potential of precision diagnosis and therapy. This work summarises recent progress in this field and particularly focuses on the application of the intestinal microbiota and metabolites in the precision diagnosis, prognosis assessment, treatment effectiveness evaluation, and therapeutic management of IBD.
炎症性肠病(IBD)是一种胃肠道慢性炎症性疾病,其发病机制被认为与共生生物和肠道免疫系统之间的失衡有关。这种失衡受到肠道微生物群和代谢产物的显著影响,并在维持肠道黏膜稳态中起关键作用。然而,肠道微生物群的紊乱会导致免疫反应失调,从而引发肠道炎症。最近的研究阐明了肠道微生物群在IBD发病机制中的作用,并强调了精准诊断和治疗的潜力。这项工作总结了该领域的最新进展,特别关注肠道微生物群和代谢产物在IBD精准诊断、预后评估、治疗效果评价及治疗管理中的应用。